Immunovant, Inc.’s IMVT share price has dipped by 11.06%, which has investors questioning if this is right time to buy.

Teacher Retirement System of Texas increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.5% ...

Leadership in pharma means questioning assumptions, amplifying diverse voices, and creating environments where authenticity ...

Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following yesterday’s topline data from the Batoclimab ...

Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Exec ...

In a report released on March 26, Yatin Suneja from Guggenheim reiterated a Buy rating on Zura Bio (ZURA – Research Report), with a price ...

Immunovant said on Wednesday its experimental treatment for a type of chronic muscle weakness improved patients' symptoms and that it aimed to use the data to accelerate the development of a newer ...

Can an AI tool be better than the industry standard at predicting which cancer patients will respond to treatment? Will drug companies feel the impacts of new cuts at the Department of Health and ...